Lankeit, Mareike

[["dc.bibliographiccitation.firstpage","916"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","CHEST Journal"],["dc.bibliographiccitation.lastpage","922"],["dc.bibliographiccitation.volume","141"],["dc.contributor.author","Lankeit, Mareike K."],["dc.contributor.author","Gomez, Vicente"],["dc.contributor.author","Wagner, Carolin"],["dc.contributor.author","Aujesky, Drahomir"],["dc.contributor.author","Recio, Monica"],["dc.contributor.author","Briongos, Sem"],["dc.contributor.author","Moores, Lisa K."],["dc.contributor.author","Yusen, Roger D."],["dc.contributor.author","Konstantinides, Stavros V."],["dc.contributor.author","Jimenez, David"],["dc.date.accessioned","2018-11-07T09:11:34Z"],["dc.date.available","2018-11-07T09:11:34Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: This study aimed to assess the performance of two prognostic models-the European Society of Cardiology (ESC) model and the simplified Pulmonary Embolism Severity Index (sPESI)-in predicting short-term mortality in patients with pulmonary embolism (PE). Methods: We compared the test characteristics of the ESC model and the sPESI for predicting 30-day outcomes in a cohort of 526 patients with objectively confirmed PE. The primary end point of the study was all-cause mortality. The secondary end point included all-cause mortality, nonfatal symptomatic recurrent VTE, or nonfatal major bleeding. Results: Overall, 40 of 526 patients died (7.6%; 95% CI, 5.3%-9.9%) during the first month of follow-up. The sPESI classified fewer patients as low risk (31% [165 of 526], 95% CI, 27%-35%) compared with the ESC model (39% [207 of 526], 95% CI, 35% to 44%; P < .01). Importantly however, low-risk patients based on the sPESI had no 30-day mortality compared with 3.4% (95% CI, 0.9-5.8) in low-risk patients by the ESC model. The secondary end point occurred in 1.8% of patients in the sPESI low-risk and 5.8% in the ESC low-risk group (difference, 4.0 percentage points; 95% CI, 0.2-7.8). The prognostic ability of the ESC model remained significant in the subgroup of patients at high-risk according to the sPESI model (OR 1.95, 95% CI, 1.41 to 2.71, P < .001). Conclusions: Both the sPESI and the ESC model successfully predict 30-day mortality after acute symptomatic PE, but exclusion of an adverse early outcome does not appear to require routine imaging procedures or laboratory biomarker testing. CHEST 2012; 141(4):916-922"],["dc.identifier.doi","10.1378/chest.11-1355"],["dc.identifier.isi","000302592700015"],["dc.identifier.pmid","21852296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26749"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Coll Chest Physicians"],["dc.relation.issn","0012-3692"],["dc.title","A Strategy Combining Imaging and Laboratory Biomarkers in Comparison With a Simplified Clinical Score for Risk Stratification of Patients With Acute Pulmonary Embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","379"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Best Practice & Research Clinical Haematology"],["dc.bibliographiccitation.lastpage","389"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Lankeit, Mareike K."],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2018-11-07T09:06:16Z"],["dc.date.available","2018-11-07T09:06:16Z"],["dc.date.issued","2012"],["dc.description.abstract","Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase or streptokinase are also efficacious. Beyond the relatively small numbers of patients with massive, high-risk PE as a target population for thrombolysis, there is increasing awareness of the need for risk stratification of normotensive patients and the search for an intermediate-risk group (also called submassive PE). Recent meta-analyses of cohort studies suggest that imaging of the right ventricle or biomarkers of myocardial injury alone may be insufficient for guiding therapeutic decisions. Instead, accumulating evidence appears to support strategies which combine the information provided by an imaging procedure with a biomarker test. These data provide the rationale for a large multinational randomized trial which has set out to determine whether normotensive patients with right ventricular dysfunction, detected by echocardiography or computed tomography, plus evidence of myocardial injury as indicated by a positive troponin test, may benefit from early thrombolytic treatment. This study, which is underway in 13 European countries, will enroll a total of 1000 patients and will be completed in 2012. Together with a parallel trial currently being conducted in the United States, it will hopefully answer the question whether thrombolysis is indicated in submassive PE, thus terminating a 40-year-old debate and filling an important gap in our management concept for acute pulmonary embolism. (c) 2012 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Boehringer Ingelheim"],["dc.identifier.doi","10.1016/j.beha.2012.06.005"],["dc.identifier.isi","000309571100015"],["dc.identifier.pmid","22959553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25515"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1521-6926"],["dc.title","Thrombolytic therapy for submassive pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","18"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.volume","118"],["dc.contributor.author","Dallas, Claudia"],["dc.contributor.author","Lankeit, Mareike K."],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.date.accessioned","2018-11-07T11:09:52Z"],["dc.date.available","2018-11-07T11:09:52Z"],["dc.date.issued","2008"],["dc.format.extent","S621"],["dc.identifier.isi","000262104501728"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53094"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","81st Annual Scientific Session of the American-Heart-Association"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.issn","0009-7322"],["dc.title","Heart-Type Fatty Acid-Binding Protein Predicts Outcome In Normotensive Patients With Pulmonary Embolism"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","769"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","783"],["dc.bibliographiccitation.volume","117"],["dc.contributor.author","Bochenek, Magdalena"],["dc.contributor.author","Rosinus, Nico"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Hobohm, Lukas"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Schütz, Eva"],["dc.contributor.author","Klok, Frederikus"],["dc.contributor.author","Horke, Sven"],["dc.contributor.author","Wiedenroth, Christoph"],["dc.contributor.author","Münzel, Thomas"],["dc.contributor.author","Lang, Irene"],["dc.contributor.author","Mayer, Eckhard"],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Schäfer, Katrin"],["dc.date.accessioned","2020-12-10T18:37:54Z"],["dc.date.available","2020-12-10T18:37:54Z"],["dc.date.issued","2017"],["dc.description.abstract","The pathomechanisms underlying the development of thrombofibrotic pulmonary artery occlusions in Chronic Thromboembolic Pulmonary Hypertension (CTEPH) are largely unknown. The aim of this study was to allocate distinct cellular processes playing a role in thrombus resolution, such as inflammation, hypoxia, proliferation, apoptosis and angiogenesis, to different stages of thrombofibrotic remodelling. A total of 182 pulmonary endarterectomy (PEA) specimens were collected from 31 CTEPH patients. To facilitate co-localisation, Tissue MicroArrays were prepared and processed for (immuno)-histochemistry and confocal fluorescence microscopy. Murine venous thrombus formation and resolution was examined after inferior vena cava ligation. PEA tissues exhibited five morphologically distinct regions predominantly consisting of either fibrin-, erythrocyte- or extracellular matrix-rich thrombus, myofibroblasts, vessels or fibrotic tissue, and were found to resemble chronological stages of thrombus resolution in mice. Cellularity was highest in vessel-rich regions, and numerous cells were strongly positive for HIFI alpha or HIF2 alpha as well as markers of activated VEGF signalling, including endothelial nitric oxide synthase. On the other hand, negative regulators of angiogenic growth factor signalling and reactive oxygen species were also highly expressed. Immune cells, primarily macrophages of the M2 subtype and CD117 haematopoietic progenitors were detected and highest in vascularised regions. Our findings demonstrate the simultaneous presence of different stages of thrombus organisation and suggest that hypoxia-induced endothelial, mesenchymal and immune cell activation may contribute to thrombofibrosis in CTEPH. This systematic histological characterisation of the material obstructing pulmonary vessels in CTEPH may provide a valuable basis for further studies aimed at determining causal factors underlying this disease."],["dc.identifier.doi","10.1160/TH16-10-0790"],["dc.identifier.eissn","2567-689X"],["dc.identifier.isi","000398880400015"],["dc.identifier.issn","0340-6245"],["dc.identifier.pmid","28150849"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77131"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0340-6245"],["dc.title","From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","140"],["dc.bibliographiccitation.issue","01"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","148"],["dc.bibliographiccitation.volume","119"],["dc.contributor.author","Kostrubiec, Maciej"],["dc.contributor.author","Pływaczewska, Magdalena"],["dc.contributor.author","Jiménez, David"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Ciurzynski, Michał"],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Pruszczyk, Piotr"],["dc.date.accessioned","2020-12-10T18:12:17Z"],["dc.date.available","2020-12-10T18:12:17Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1055/s-0038-1676522"],["dc.identifier.eissn","2567-689X"],["dc.identifier.issn","0340-6245"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74315"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","996"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","1003"],["dc.bibliographiccitation.volume","111"],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Tschepe, Merle"],["dc.contributor.author","Seeber, Valerie"],["dc.contributor.author","Zwiener, Isabella"],["dc.contributor.author","Kuhnert, Katherina"],["dc.contributor.author","Schaefer, Katrin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Lankeit, Mareike"],["dc.date.accessioned","2017-09-07T11:46:17Z"],["dc.date.available","2017-09-07T11:46:17Z"],["dc.date.issued","2014"],["dc.description.abstract","We tested whether heart-type fatty acid binding protein (H-FABP) measured by a fully-automated immunoturbidimetric assay in comparison to ELISA provides additive prognostic value in patients with pulmonary embolism (PE), and validated a fast prognostic score in comparison to the ESC risk prediction model and the simplified Pulmonary Embolism Severity Index (sPESI). We prospectively examined 271 normotensive patients with PE; of those, 20 (7%) had an adverse 30-day outcome. H-FABP levels determined by immunoturbidimetry were higher (median, 5.2 [IQR; 2.7-9.8] ng/ml) than those by ELISA (2.9 [1.1-5.4] ng/ml), but Bland-Altman plot demonstrated a good agreement of both assays. The area under the curve for H-FABP was greater for immunoturbidimetry than for ELISA (0.82 [0.74-0.91] vs 0.78 [0.68-0.89]; P=0.039). H-FABP measured by immunoturbidimetry (but not by ELISA) provided additive prognostic information to other predictors of 30-day outcome (OR, 12.4 [95% CI, 1.6-97.6]; P=0.017).When H-FABP determined by immunoturbidimetry was integrated into a novel prognostic score (H-FABP, Syncope, and Tachycardia; FAST score), the score provided additive prognostic information by multivariable analysis (OR, 14.2 [3.9-51.4]; p<0.001; c-index, 0.86) which were superior to information obtained by the ESC model(c-index, 0.62; net reclassification improvement (NRI), 0.39 [0.21-0.56]; P<0.001) or the sPESI (c-index, 0.68; NRI, 0.24 [0.05-0.43]; P=0.012). In conclusion, determination of H-FABP by immunoturbidimetry provides prognostic information superior to that of ELISA and, if integrated in the FAST score, appears more suitable to identify patients with an adverse 30-day outcome compared to the ESC model and sPESI."],["dc.identifier.doi","10.1160/TH13-08-0663"],["dc.identifier.gro","3142135"],["dc.identifier.isi","000335541500025"],["dc.identifier.pmid","24477222"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/4933"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0340-6245"],["dc.title","A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Polish Archives of Internal Medicine"],["dc.contributor.author","Pruszczyk, Piotr"],["dc.contributor.author","Kurnicka, Katarzyna"],["dc.contributor.author","Ciurzyński, Michał"],["dc.contributor.author","Hobohm, Lukas"],["dc.contributor.author","Thielmann, Aaron"],["dc.contributor.author","Sobkowicz, Bożena"],["dc.contributor.author","Sawicka, Emilia"],["dc.contributor.author","Kostrubiec, Maciej"],["dc.contributor.author","Ptaszyńska-Kopczyńska, Katarzyna"],["dc.contributor.author","Dzikowska-Diduch, Olga"],["dc.contributor.author","Lichodziejewska, Barbara"],["dc.contributor.author","Lankeit, Mareike"],["dc.date.accessioned","2021-04-14T08:32:41Z"],["dc.date.available","2021-04-14T08:32:41Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.20452/pamw.15459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83985"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","1897-9483"],["dc.title","Defining right ventricular dysfunction by the use of echocardiography in normotensive patients with pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","796"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Thrombosis Research"],["dc.bibliographiccitation.lastpage","801"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Klok, F. A."],["dc.contributor.author","Tesche, C."],["dc.contributor.author","Rappold, L."],["dc.contributor.author","Dellas, Claudia"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Huisman, M. V."],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Lankeit, Mareike"],["dc.date.accessioned","2017-09-07T11:44:25Z"],["dc.date.available","2017-09-07T11:44:25Z"],["dc.date.issued","2015"],["dc.description.abstract","Purpose: International guidelines do not provide strong recommendations on the duration and intensity of follow-up after acute pulmonary embolism(PE), nor on screening-programs for chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to address this gab by performing an external validation of the easy \"CTEPH rule-out-criteria\" based on a normal NT-proBNP level and the absence of 3 ECG characteristics. Methods: 134 patients underwent clinical follow-up 6 months after PE. Predefined transthoracic echocardiographic (TTE) criteria were used to categorize patients as \"PH unlikely\" or \"PH possible/likely\". The latter patients underwent further (invasive) diagnostic procedures to confirm and classify the diagnosis of pulmonary hypertension. NT-proBNP and ECGs, both assessed at the day of echocardiography, were evaluated post-hoc. Results: Sixty-three patients (47%) scored none of the \"CTEPH rule-out criteria\" positive, of whom 61 had normal TTE (97%). Twenty-five patients (19%) were categorized by TTE as \"PH possible/likely\"; of those, 6 were diagnosed with CTEPH. The sensitivity of rule-out criteria for CTEPH was 100% (95%CI 56-100%; 6/6 patients identified), and for \"PH possible/likely\" on TTE 92% (95%CI 74-99%; 23/25 patients identified): 2 asymptomatic patients with estimated systolic pulmonary arterial pressure of 36 mmHg and 38 mmHg, respectively, who remained stable during further 2-year follow-up, were not identified. Inter-observer agreement for the adjudication of the ECG characteristics was excellent (kappa-statistic 0.97). Conclusions: In this external validation cohort, we confirmed the diagnostic accuracy and reproducibility of the \"CTEPH rule-out criteria\". These results provide a solid ground for future outcome trials applying this algorithm. (C) 2014 Published by Elsevier Ltd."],["dc.identifier.doi","10.1016/j.thromres.2014.12.009"],["dc.identifier.gro","3141915"],["dc.identifier.isi","000353490800005"],["dc.identifier.pmid","25746363"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2489"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0049-3848"],["dc.title","External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","ehw597"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.contributor.author","Hoeper, Marius M."],["dc.contributor.author","Lam, Carolyn S.P."],["dc.contributor.author","Vachiery, Jean-Luc"],["dc.contributor.author","Bauersachs, Johann"],["dc.contributor.author","Gerges, Christian"],["dc.contributor.author","Lang, Irene M."],["dc.contributor.author","Bonderman, Diana"],["dc.contributor.author","Olsson, Karen M."],["dc.contributor.author","Gibbs, J. Simon R."],["dc.contributor.author","Dorfmuller, Peter"],["dc.contributor.author","Guazzi, Marco"],["dc.contributor.author","Galiè, Nazzareno"],["dc.contributor.author","Manes, Alessandra"],["dc.contributor.author","Handoko, M. Louis"],["dc.contributor.author","Vonk-Noordegraaf, Anton"],["dc.contributor.author","Lankeit, Mareike"],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Opitz, Christian"],["dc.contributor.author","Rosenkranz, Stephan"],["dc.date.accessioned","2020-12-10T18:19:01Z"],["dc.date.available","2020-12-10T18:19:01Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1093/eurheartj/ehw597"],["dc.identifier.eissn","1522-9645"],["dc.identifier.issn","0195-668X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75115"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research†"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","121"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Thrombosis and Haemostasis"],["dc.bibliographiccitation.lastpage","128"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Klok, F. A."],["dc.contributor.author","Dzikowska-Diduch, O."],["dc.contributor.author","Kostrubiec, Maciej"],["dc.contributor.author","Vliegen, H. W."],["dc.contributor.author","Pruszczyk, Piotr"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Huisman, M. V."],["dc.contributor.author","Konstantinides, Stavros"],["dc.contributor.author","Lankeit, Mareike"],["dc.date.accessioned","2017-09-07T11:54:44Z"],["dc.date.available","2017-09-07T11:54:44Z"],["dc.date.issued","2016"],["dc.description.abstract","Introduction: Validated risk factors for the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) after acute pulmonary embolism (PE) are currently lacking. Methods: This is a post hoc patient-level analysis of three large prospective cohorts with a total of 772 consecutive patients with acute PE, without major cardiopulmonary or malignant comorbidities. All underwent echocardiography after a median of 1.5 years. In cases with signs of pulmonary hypertension, additional diagnostic tests to confirm CTEPH were performed. Baseline demographics and clinical characteristics of the acute PE event were included in a multivariable regression analysis. Independent predictors were combined in a clinical prediction score. Results: CTEPH was confirmed in 22 patients (2.8%) by right heart catheterization. Unprovoked PE, known hypothyroidism, symptom onset > 2 weeks before PE diagnosis, right ventricular dysfunction on computed tomography or echocardiography, known diabetes mellitus and thrombolytic therapy or embolectomy were independently associated with a CTEPH diagnosis during follow-up. The area under the receiver operating charateristic curve (AUC) of the prediction score including those six variables was 0.89 (95% confidence interval [ CI] 0.84-0.94). Sensitivity analysis and bootstrap internal validation confirmed this AUC. Seventy-three per cent of patients were in the low-risk category (CTEPH incidence of 0.38%, 95% CI 0-1.5%) and 27% were in the high-risk category (CTEPH incidence of 10%, 95% CI 6.5-15%). Conclusion: The 'CTEPH prediction score' allows for the identification of PE patients with a high risk of CTEPH diagnosis after PE. If externally validated, the score may guide targeting of CTEPH screening to at-risk patients."],["dc.identifier.doi","10.1111/jth.13175"],["dc.identifier.gro","3141751"],["dc.identifier.isi","000370661100014"],["dc.identifier.pmid","26509468"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/668"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: German Federal Ministry of Education and Research [BMBF 01EO1003]"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley-blackwell"],["dc.relation.eissn","1538-7836"],["dc.relation.issn","1538-7933"],["dc.title","Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]